4.8 Review

Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease

期刊

HEPATOLOGY
卷 75, 期 4, 页码 1026-1037

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.32143

关键词

-

向作者/读者索取更多资源

ALD is becoming a major cause of liver-related mortality and transplantation globally. Research methodologies focused on diagnosing, treating, and predicting ALD and AH were discussed at the scientific sessions.
Alcohol-associated liver disease (ALD) is emerging worldwide as the leading cause of liver-related morbidity, mortality, and indication for liver transplantation. The ALD Special Interest Group and the Clinical Research Committee at the digital American Association for the Study of Liver Diseases meeting in November 2020 held the scientific sessions to identify clinical unmet needs in ALD, and addressing these needs using clinical research methodologies. Of several research methodologies, the sessions were focused on (a) studying disease burden of ALD using large administrative databases, (b) developing biomarkers for noninvasive diagnosis of alcohol-associated hepatitis (AH) and estimation of disease prognosis, (c) identifying therapeutic targets for ALD and AH, (d) deriving accurate models to predict prognosis or posttransplant alcohol relapse as a basis for developing treatment algorithm and a uniform protocol on patient-selection criteria for liver transplantation, and (e) examining qualitative research methodologies in studying the barriers to implementation of multidisciplinary integrated care model by hepatology and addiction teams for the management of dual pathology of liver disease and of alcohol use disorder. Prospective multicenter studies are required to address many of these clinical unmet needs. Further, multidisciplinary care models are needed to improve long-term outcomes in patients with ALD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Impact of Donor Liver Macrovesicular Steatosis on Deceased Donor Yield and Posttransplant Outcome

Allison J. Kwong, W. Ray Kim, John Lake, Peter G. Stock, Connie J. Wang, James B. Wetmore, Marc L. Melcher, Andrew Wey, Nicholas Salkowski, Jon J. Snyder, Ajay K. Israni

Summary: A study found that livers with macrovesicular steatosis are less likely to be transplanted due to their higher risk of graft failure. To facilitate the use of these higher-risk organs, the SRTR now includes the variable of macrovesicular steatosis in their risk-adjustment models.

TRANSPLANTATION (2023)

Article Gastroenterology & Hepatology

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

Alexandre Louvet, Valerie Bourcier, Isabelle Archambeaud, Louis d'Alteroche, Cendrine Chaffaut, Frederic Oberti, Christophe Moreno, Dominique Roulot, Thong Dao, Romain Moirand, Jean-Charles Duclos-Vallee, Odile Goria, Eric Nguyen-Khac, Stanislas Pol, Nicolas Carbonell, Jerome Gournay, Laure Elkrief, Isabelle Fouchard-Hubert, Sylvie Chevret, Nathalie Ganne-Carrie

Summary: This study aims to investigate the factors influencing the long-term prognosis of patients with alcohol-related cirrhosis. The results showed that alcohol recurrence and moderate alcohol consumption were associated with poor outcomes. It is recommended that patients with alcohol-related cirrhosis should completely abstain from drinking alcohol.

JOURNAL OF HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Response to: Towards optimally replacing the current version of MELD

Jin Ge, W. Ray Kim, Jennifer C. Lai, Allison J. Kwong

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis

Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W. Ray Kim, Leland J. Yee, Craig Brooks-Rooney, Tristan Curteis, Harriet Cant, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Woo Kim, Neung Hwa Park, Cheng-Yuan Peng, Hyun Phil Shin, Woo Shin, Yao-Hsu Yang, Young-Suk Lim

Summary: This study compared the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) treatment. The results showed that patients receiving TDF had a significantly lower HCC risk, especially those with HBeAg positivity.

JOURNAL OF HEPATOLOGY (2023)

Article Nutrition & Dietetics

Original PNPLA3 genotypes modify the adverse effect of the total energy intake on high-risk nonalcoholic steatohepatitis development

Heejun Son, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jeong Hwan Park, Mee Soo Chang, Won Kim

Summary: This study aimed to investigate the effects of diet on the development of nonalcoholic steatohepatitis (NASH) and fibrosis progression in patients with nonalcoholic fatty liver disease (NAFLD). The total energy intake had no impact on fibrosis progression but was associated with high-risk NASH. The effect of total energy intake on high-risk NASH was more pronounced in patients without the PNPLA3 risk allele.

AMERICAN JOURNAL OF CLINICAL NUTRITION (2023)

Review Transplantation

Optimizing liver transplant prioritization for hepatocellular carcinoma through risk stratification

Joshua Norman, Neil Mehta, Allison Kwong

Summary: A more nuanced allocation scheme for hepatocellular carcinoma (HCC) is needed to represent the individual urgency for liver transplant and optimize organ utility. Several risk prediction models have been proposed but none have been adopted in clinical practice or liver allocation due to limitations.

CURRENT OPINION IN ORGAN TRANSPLANTATION (2023)

Review Gastroenterology & Hepatology

Current and future treatment for alcoholic-related liver diseases

Eileen L. L. Yoon, Won Kim

Summary: The socioeconomic burden of alcohol-related liver disease is increasing globally. Its prevalence is underestimated and early diagnosis is rare. Alcoholic hepatitis, a life-threatening syndrome, is characterized by systemic inflammation. Prednisolone is the first-line treatment for severe alcoholic hepatitis, with liver transplantation as an option for non-responders. Abstinence is crucial for long-term care, and new therapeutic targets aim to prevent hepatic inflammation, reduce oxidative stress, improve gut dysbiosis, and enhance liver regeneration. This review covers the pathogenesis, current treatment, and barriers to clinical trials of alcoholic hepatitis, as well as ongoing or recently completed trials.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Evaluation of the transplantation of ACLF grade 3 model (TAM) in the multicenter French experience

Florent Artru, Sophie-Caroline Sacleux, Jose Ursic-Bedoya, Georges-Philippe Pageaux, Alexandre Louvet, Faouzi Saliba

LIVER TRANSPLANTATION (2023)

Editorial Material Gastroenterology & Hepatology

Introducing W. Ray Kim, MD, Our 2024 AASLD president

Young-Suk Lim, Allison Kwong, Alina M. Allen

HEPATOLOGY (2023)

Article Medicine, General & Internal

Hepatitis C Screening in Post-Baby Boomer Generation Americans: One Size Does Not Fit All

Pimsiri Sripongpun, Prowpanga Udompap, Ajitha Mannalithara, N. Lance Downing, Anna A. Vidovszky, Allison J. Kwong, Aparna Goel, Paul Y. Kwo, W. Ray Kim

Summary: The study aims to analyze the impact of health insurance coverage on HCV infection prevalence in US adults born after 1965 and formulate strategies for population screening. The results show higher HVC prevalence in uninsured individuals, and alanine aminotransferase prescreening can effectively reduce the number of screenings.

MAYO CLINIC PROCEEDINGS (2023)

Review Gastroenterology & Hepatology

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Luis Antonio Diaz, Juan Pablo Arab, Alexandre Louvet, Ramon Bataller, Marco Arrese

Summary: In this Review, Arrese and colleagues discuss the pathophysiology, clinical management, and future research directions of nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), which are the leading causes of chronic liver disease worldwide. The authors highlight the shared features and interactions between alcohol and metabolic dysfunction in the development and progression of liver disease, as well as the under-reporting of alcohol consumption in patients classified as having NAFLD. They propose the evaluation of both metabolic syndrome and alcohol consumption in patients with fatty liver disease to improve prognosis and personalize treatment.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

Therapeutic targets in alcohol-associated liver disease: progress and challenges

Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, Ashwani K. K. Singal

Summary: Alcohol-associated liver disease (ALD) is a complex and rapidly increasing disease without approved therapeutic targets. Challenges in study designs and clinical trials need to be overcome to drive drug development in this field. ALD management should focus on achieving and maintaining alcohol abstinence, while early liver transplantation protocols and noninvasive biomarkers require improvement. Integrated multidisciplinary care models are urgently needed to improve long-term outcomes for ALD patients with alcohol use disorder and liver disease.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Review Medicine, General & Internal

Advances in the understanding and management of alcohol-related liver disease

Mark Thursz, Anne Lingford-Hughes

Summary: Alcohol-related liver disease (ALD) is a leading contributor to liver-related morbidity and mortality, and its burden is increasing. The disease is influenced by genetic susceptibility and environmental factors. Despite long-term excessive alcohol consumption, most patients are diagnosed at an advanced stage, missing opportunities for intervention. Non-invasive tests have shown promise in early detection. Public health measures and individual interventions have limited ability to reduce the disease burden due to a lack of effective interventions. Abstinence from alcohol is crucial for established ALD patients, and liver transplant is indicated in cases of decompensated ALD. Understanding the mechanisms of alcohol-induced liver disease offers potential for new treatments, but funding in this area has been historically inadequate.

BMJ-BRITISH MEDICAL JOURNAL (2023)

Review Gastroenterology & Hepatology

Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin

Ashwani K. Singal, Lorenzo Leggio, Andrea DiMartini

Summary: Alcohol-associated liver disease (ALD) is a leading cause for liver transplantation (LT) globally, particularly during the COVID-19 pandemic and among young individuals. Alcohol use disorder (AUD) is prevalent in the majority of ALD patients, and early liver transplantation (eLT) has emerged as a potential treatment for selected patients with alcohol-associated hepatitis. However, the challenge lies in addressing AUD treatment, which requires an integrated multidisciplinary care approach.

LIVER TRANSPLANTATION (2023)

暂无数据